SAN DIEGO--(BUSINESS WIRE)--Human Longevity, Inc. (“HLI”), an innovator in providing data-driven precision health intelligence platform for physicians and patients, today announced a $30 million financing from veteran biotech investment firms and investors. Existing investor Emerging Technology Partners LLC participated in the financing with other new dedicated healthcare investors. HLI will use the proceeds from this financing to enhance our Health Nucleus intelligence platform, which is using integrated metrics derived from specialized imaging, whole genome sequencing and other lab tests with machine learning and AI to create a comprehensive standard for measuring your health and performance.

ABOUT HUMAN LONGEVITY

Human Longevity provides unparalleled, precision health analytics to individuals through the Health Nucleus assessment in La Jolla, CA. The Health Nucleus provides risk analyses for cardiac, cancer, metabolic and cognitive issues. This is provided via integrated looks at the individual’s whole genome sequencing, brain and body imaging via MRI, cardiac CAT scan, metabolic tests and more, using machine learning and artificial intelligence.